021-51111890
购物车（）
sales@molnova.cn
Brivanib
CAS No. 649735-46-6
Brivanib ( BMS-540215;BMS540215;BMS 540215 )
产品货号. M15465 CAS No. 649735-46-6
A dual inhibitor of VEGFR2 and FGFR1 with IC50 of 25 nM and 148 nM respectively.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥567 | 有现货 |
|
| 5MG | ￥899 | 有现货 |
|
| 10MG | ￥1482 | 有现货 |
|
| 25MG | ￥3021 | 有现货 |
|
| 50MG | ￥4609 | 有现货 |
|
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Brivanib
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述A dual inhibitor of VEGFR2 and FGFR1 with IC50 of 25 nM and 148 nM respectively.
-
产品描述A dual inhibitor of VEGFR2 and FGFR1 with IC50 of 25 nM and 148 nM respectively; shows weak activity for VEGFR1 (IC50=380 nM), and no significant activity on EGFR, PDGFRβ, Lck, etc.; demonstrates robust in vivo activity in human tumor xenograft models.Liver Cancer Phase 3 Clinical
-
同义词BMS-540215;BMS540215;BMS 540215
-
通路Angiogenesis
-
靶点VEGFR
-
受体EGFR;FGFR1;Flk1;VEGFR1;VEGFR2
-
研究领域Cancer
-
适应症Liver Cancer
化学信息
-
CAS Number649735-46-6
-
分子量370.38
-
分子式C19H19FN4O3
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 50 mg/mL
-
SMILESFC1=C(OC2=NC=NN3C2=C(C(OC[C@H](O)C)=C3)C)C=CC4=C1C=C(C)N4
-
化学全称2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Bhide RS, et al. J Med Chem. 2006 Apr 6;49(7):2143-6.
2. Bhide RS, et al. Mol Cancer Ther. 2010 Feb;9(2):369-78.
3. Huynh H, et al. Clin Cancer Res. 2008 Oct 1;14(19):6146-53.
2. Bhide RS, et al. Mol Cancer Ther. 2010 Feb;9(2):369-78.
3. Huynh H, et al. Clin Cancer Res. 2008 Oct 1;14(19):6146-53.
产品手册
关联产品
-
Fruquintinib
A potent and highly selective small molecule inhibitor of VEGFR1/2/3 with IC50 of 33/3/5/0.5 nM, respectively.
-
AG-13958
AG-13958 (AG-013958) a potent VEGFR tyrosine kinase inhibitor ?for the treatment of age-related macular degeneration.
-
Lenvatinib mesylate
Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
